CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 Trial to Evaluate the Safety of IL13Rα2-Targeting Chimeric Antigen Receptor (CAR) T Cells With CRISPR Knockout of TGFβR2 in Patients With Recurrent or Progressive High-Grade Glioma (HGG)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06815029
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:39.245513+00:00
Published At: 2025-06-26T00:00:00+00:00
Record Updated At: 2025-06-26
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Recurrent Astrocytoma, IDH-Mutant, Grade 3", "Recurrent Astrocytoma, IDH-Mutant, Grade 4", "Recurrent Glioblastoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-06-26"
protocolSection.identificationModule.nctId: "NCT06815029"
protocolSection.identificationModule.officialTitle: "A Phase 1 Trial to Evaluate the Safety of IL13R\u03b12-Targeting Chimeric Antigen Receptor (CAR) T Cells With CRISPR Knockout of TGF\u03b2R2 in Patients With Recurrent or Progressive High-Grade Glioma (HGG)"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.